Truist Downgrades Alnylam Pharmaceuticals to Hold Due to Amvuttra Sales Uncertainty
Truist analyst Fabrice Cabaud has downgraded Alnylam Pharmaceuticals (ALNY) from 'buy' to 'hold.' The downgrade is primarily driven by concerns regarding the sales outlook for Amvuttra (vutrisiran), a therapy used to treat hereditary transthyretin-mediated amyloidosis. As part of this rating change, Truist significantly reduced its price target for Alnylam from $315 down to $225. This adjustment reflects a more cautious stance on the company's near-term revenue clarity and growth trajectory for its key amyloidosis treatment.
Tickers: $ALNY